ProCE Banner Activity

MAPS: Adding Bevacizumab to Pemetrexed/Cisplatin Increases Survival in Patients With Malignant Pleural Mesothelioma

Slideset Download
Conference Coverage
Results of phase II/III trial suggest that Bevacizumab/Pemetrexed/Cisplatin is a new treatment option although increased toxicity is a potential concern

Released: June 02, 2015

Expiration: May 31, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation